Rare diseases, Portugal and ophan drugs
With the adoption of Regulation (EC) No 141/2000 of the European Commission, conditions were created for the development of orphan drugs and, as a result, the Committee for Orphan Medicinal
Biocant International
P-BIO and Biocant joined forces to carry out a programme to support the internationalization of Portuguese small and medium-sized enterprises (SME) in the biotechnology sector. The Programme included: • Creating
Emerging business models and technological platforms: new methods of creating and appropriating value in the biomedical industry
An FCT Project approved and led by IN+ with P-BIO and ISCTE, which investigated the role of technological platforms originating from science in generating variety, and the mechanisms and processes
Bioreg – SOE3/P1/E750 was a project co-financed by the SUDOE Territorial Program
Mission: Development of cell therapies and regenerative medicine within the SUDOE space. Led by the Fundación Andaluza de I+D with the participation of PBIO, Instituto Superior Técnico de Lisboa, Jean
ECOBIOFOR
P-BIO participates in ECOBIOFOR. The goal of this project is to develop new biosolvents using new chemical and bio processes. Project FP7 under the leadership of Tecnália and with the
Opportunity Now, Europe’s Mission to Innovate
Robert Madelin's report | 5 July 2016
